Epstein barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation

PLoS Pathogens

Volumn 6, Issue 10, 2010, Pages

  Apcher, Sebastien ^a   Daskalogianni, Chrysoula ^a   Manoury, Benedicte ^b   Fåhraeus, Robin ^a  

^a INSERM   (France)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; DIPEPTIDE; EBV ENCODED NUCLEAR ANTIGEN 1; EBV-ENCODED NUCLEAR ANTIGEN 1; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; HLA ANTIGEN CLASS 1; INITIATION FACTOR; N GLYCYLALANINE; N-GLYCYLALANINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FIBROBLAST; HOST CELL; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; LUNG CARCINOMA; LYMPHOMA; MELANOMA; MOUSE; NONHUMAN; OSTEOSARCOMA; RNA TRANSLATION; TRANSLATION INITIATION; VIRUS DETECTION; VIRUS IMMUNITY; VIRUS INTERFERENCE; AMINO ACID SEQUENCE; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; CONFORMATION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNE EVASION; IMMUNOLOGY; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROTEIN SYNTHESIS; TUMOR CELL LINE;

HUMAN HERPESVIRUS 4;

ANIMALS; ANTIGEN PRESENTATION; BASE SEQUENCE; CELL LINE, TUMOR; DIPEPTIDES; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; EUKARYOTIC INITIATION FACTORS; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; IMMUNODOMINANT EPITOPES; MICE; MODELS, BIOLOGICAL; NUCLEIC ACID CONFORMATION; PROTEIN BIOSYNTHESIS; REPETITIVE SEQUENCES, AMINO ACID; RNA, MESSENGER;

EID: 78449257073     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1001151     Document Type: Article

References (42)

1. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, et al. (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771.
2. Rock KL, York IA, Goldberg AL (2004) Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 5: 670-677.
3. Kloetzel PM (2004) Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII. Nat Immunol 5: 661-669.
4. Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S (1992) TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell 71: 1205-1214.
5. Serwold T, Gonzalez F, Kim J, Jacob R, Shastri N (2002) ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419: 480-483.
6. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG (1991) Allelespecific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351: 290-296.
7. Goldberg AL, Dice JF (1974) Intracellular protein degradation in mammalian and bacterial cells. Annu Rev Biochem 43: 835-869.
8. Qian SB, Reits E, Neefjes J, Deslich JM, Bennink JR, et al. (2006) Tight linkage between translation and MHC class I peptide ligand generation implies specialized antigen processing for defective ribosomal products. J Immunol 177: 227-233.
9. Yewdell JW, Anton LC, Bennink JR (1996) Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol 157: 1823-1826.
10. Reits EA, Vos JC, Gromme M, Neefjes J (2000) The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 404: 774-778.
11. Shastri N, Cardinaud S, Schwab SR, Serwold T, Kunisawa J (2005) All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol Rev 207: 31-41.
12. Yewdell JW, Bennink JR (1999) Mechanisms of viral interference with MHC class I antigen processing and presentation. Annu Rev Cell Dev Biol 15: 579-606.
13. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL (2000) Viral subversion of the immune system. Annu Rev Immunol 18: 861-926.
14. Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB (1992) Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 66: 122-131.
15. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, et al. (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375: 685-688.
16. Blake N, Lee S, Redchenko I, Thomas W, Steven N, et al. (1997) Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)- containing protein requires exogenous processing. Immunity 7: 791-802.
17. Bennett NJ, May JS, Stevenson PG (2005) Gamma-herpesvirus latency requires T cell evasion during episome maintenance. PLoS Biol 3: e120.
18. Kwun HJ, da Silva SR, Shah IM, Blake N, Moore PS, et al. (2007) Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mimics Epstein-Barr virus EBNA1 immune evasion through central repeat domain effects on protein processing. J Virol 81: 8225-8235.
19. Apcher S, Komarova A, Daskalogianni C, Yin Y, Malbert-Colas L, et al. (2009) mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1. J Virol 83: 1289-1298.
20. Yin Y, Manoury B, Fahraeus R (2003) Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301: 1371-1374.
21. Shastri N, Gonzalez F (1993) Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells. J Immunol 150: 2724-2736.
22. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J (1994) Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 180: 1471-1483.
23. Karttunen J, Sanderson S, Shastri N (1992) Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci U S A 89: 6020-6024.
24. Daskalogianni C, Apcher S, Candeias MM, Naski N, Calvo F, et al. (2008) Gly- Ala repeats induce position- and substrate-specific regulation of 26 S proteasome-dependent partial processing. J Biol Chem 283: 30090-30100.
25. Schwab SR, Li KC, Kang C, Shastri N (2003) Constitutive display of cryptic translation products by MHC class I molecules. Science 301: 1367-1371.
26. Shastri N, Nguyen V, Gonzalez F (1995) Major histocompatibility class I molecules can present cryptic translation products to T-cells. J Biol Chem 270: 1088-1091.
27. Navon A, Goldberg AL (2001) Proteins are unfolded on the surface of the ATPase ring before transport into the proteasome. Mol Cell 8: 1339-1349.
28. York IA, Goldberg AL, Mo XY, Rock KL (1999) Proteolysis and class I major histocompatibility complex antigen presentation. Immunol Rev 172: 49-66.
29. Kloetzel PM, Ossendorp F (2004) Proteasome and peptidase function in MHCclass- I-mediated antigen presentation. Curr Opin Immunol 16: 76-81.
30. Nanbru C, Lafon I, Audigier S, Gensac MC, Vagner S, et al. (1997) Alternative translation of the proto-oncogene c-myc by an internal ribosome entry site. J Biol Chem 272: 32061-32066.
31. Creancier L, Mercier P, Prats AC, Morello D (2001) c-myc Internal ribosome entry site activity is developmentally controlled and subjected to a strong translational repression in adult transgenic mice. Mol Cell Biol 21: 1833-1840.
32. Stoneley M, Subkhankulova T, Le Quesne JP, Coldwell MJ, Jopling CL, et al. (2000) Analysis of the c-myc IRES; a potential role for cell-type specific transacting factors and the nuclear compartment. Nucleic Acids Res 28: 687-694.
33. Le Quesne JP, Stoneley M, Fraser GA, Willis AE (2001) Derivation of a structural model for the c-myc IRES. J Mol Biol 310: 111-126.
34. Blake NW, Moghaddam A, Rao P, Kaur A, Glickman R, et al. (1999) Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1. J Virol 73: 7381-7389.
35. Mackay LK, Long HM, Brooks JM, Taylor GS, Leung CS, et al. (2009) T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display. PLoS Pathog 5: e1000699.
36. Cardinaud S, Starck SR, Chandra P, Shastri N (2010) The synthesis of truncated polypeptides for immune surveillance and viral evasion. PLoS One 5: e8692.
37. Tellam J, Smith C, Rist M, Webb N, Cooper L, et al. (2008) Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. Proc Natl Acad Sci U S A 105: 9319-9324.
38. Norseen J, Thomae A, Sridharan V, Aiyar A, Schepers A, et al. (2008) RNAdependent recruitment of the origin recognition complex. EMBO J 27: 3024-3035.
39. Yewdell JW, Reits E, Neefjes J (2003) Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol 3: 952-961.
40. Khan S, de Giuli R, Schmidtke G, Bruns M, Buchmeier M, et al. (2001) Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. J Immunol 167: 4801-4804.
41. Fahraeus R (2005) Do peptides control their own birth and death? Nat Rev Mol Cell Biol 6: 263-267.
42. Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27.